Access Bio Inc

950130 · KQ · Healthcare / Diagnostics & Research

1,719.00KRW-26.00 (-1.49%)

Price History

Full chart

Market Stats

Previous Close1,745.00

Open1,730.00

Day Range1,711.00 – 1,799.00

52-Week Range1,945.00 – 5,280.00

Volume32.29K

Market Cap76.50B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.37

50-Day Avg2,323.70

200-Day Avg2,977.90

About

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEOMr. Young-Ho Choi
Employees0
Headquarters65 Clyde Road, Somerset, NJ, United States, 08873, Korea
Websitehttps://accessbio.net

Leadership

Mr. Young-Ho ChoiCEO & President · b. 1964
Bo-Kyung ChoiManaging Director
Mr. John KimManaging Partner
Young-Seok HongManaging Director
Mr. Philip Kim CPATreasurer and Member of the Advisory Board
Ms. Janet Strong Ph.D.DOD/Government Issues Advisor and Member of the Advisory Board
Mr. Andrew J. Gorman CPA, Ph.D.Business Advisor and Member of the Advisory Board
N. A. Shaikh M.D., Ph.D.Clinical Advisor and Member of the Advisory Board

Financials

Income Statement

Currency: KRW	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	37.00B	45.84B	32.30B	35.58B	27.99M	26.06M	36.57M	36.94M	103.21M	441.37M	800.23M	267.08M	82.45M	31.26B
Growth (%)	-	+23.90%	-29.53%	+10.15%	-99.92%	-6.92%	+40.36%	+1.01%	+179.41%	+327.63%	+81.31%	-66.63%	-69.13%	+37807.07%
Cost of Revenue	15.29B	22.07B	16.85B	24.03B	15.87M	17.97M	22.40M	28.87M	26.31M	95.00M	165.72M	136.65M	43.13M	55.70B
Gross Profit	21.70B	23.77B	15.45B	11.55B	12.12M	8.09M	14.17M	8.07M	76.90M	346.37M	634.52M	130.43M	39.32M	-24.45B
Gross Margin	58.66%	51.87%	47.84%	32.46%	43.29%	31.03%	38.75%	21.85%	74.51%	78.48%	79.29%	48.84%	47.69%	-78.22%
Operating Expense	13.21B	12.39B	13.13B	11.54B	12.72M	14.53M	18.75M	21.98M	21.12M	119.22M	271.42M	112.38M	43.44M	38.84B
Operating Income	8.49B	11.38B	2.32B	6.00M	-601.19K	-6.45M	-4.58M	-13.91M	55.78M	227.15M	363.10M	18.05M	-4.12M	-63.29B
Operating Margin	22.96%	24.83%	7.18%	0.02%	-2.15%	-24.74%	-12.52%	-37.65%	54.05%	51.46%	45.37%	6.76%	-5.00%	-202.48%
EBITDA	-	-	-	-	-	-	-	-	-	-	480.76B	13.79B	23.40B	-85.90B
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	60076.86%	5163.79%	28384.89%	-274.84%
Net Income	7.45B	7.84B	2.43B	1.26B	262.09K	-5.74M	-3.85M	-15.09M	40.91M	165.75M	268.33M	-2.43M	-254.83K	-82.12B
Net Income Margin	20.14%	17.10%	7.53%	3.56%	0.94%	-22.01%	-10.54%	-40.85%	39.63%	37.55%	33.53%	-0.91%	-0.31%	-262.74%
R&D	-	-	-	-	-	-	-	-	4.01B	4.89B	7.32B	16.08B	10.84B	8.48B
R&D as % of Total Revenue	-	-	-	-	-	-	-	-	3881.59%	1108.81%	914.18%	6020.96%	13143.94%	27.14%
Interest Expense	0	0	0	0	0	0	0	0	1.87B	3.35B	6.23B	3.71B	3.47B	2.32B
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1808.87%	758.93%	778.92%	1389.39%	4208.53%	7.42%

Balance Sheet

Currency: KRW	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	29.09B	59.19B	78.93B	81.12B	91.22M	87.15M	84.82M	60.23M	156.42M	372.85M	698.71M	691.14B	503.98M	607.94B
Total Liabilities	7.38B	8.99B	10.35B	4.24B	43.68M	46.03M	51.40M	39.01M	79.47M	131.10M	210.97M	104.00B	61.70M	49.45B
Total Equity	-	-	-	-	47.55M	41.13M	33.42M	21.22M	76.95M	241.75M	487.74M	584.16B	442.28M	557.19B
Cash	1.09B	18.19B	3.97B	7.03B	5.90K	5.46M	4.59M	5.90M	45.23M	3.90K	7.53K	277.61B	232.82M	323.34B
Total Debt	-	-	-	-	24.08M	18.12M	23.81M	21.02M	34.88M	-	-	-	-	-
Net Debt	-	-	-	-	-	-	-	29.32B	-	-	-	-	-	-

Cash Flow

Currency: KRW	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	1.85B	1.59B	-2.63B	2.87B	2.11M	-5.45B	-5.73B	-422.24M	36.72B	137.90M	291.33M	-80.57M	13.54M	-29.18B
Investing Cash Flow	-2.30B	-6.22B	-25.95B	30.00M	-9.74M	-11.64B	-4.87B	3.19B	-8.81B	-29.46M	-29.79M	-36.06M	11.88M	-
Financing Cash Flow	-156.00M	21.44B	15.57B	1.34B	23.14M	1.71B	8.65B	-707.48M	15.33B	15.19M	-53.19M	-41.87M	-5.14M	-
Capital Expenditure	1.31B	2.63B	5.90B	4.85B	10.03M	4.20B	1.67B	3.05B	10.38B	28.76M	14.90M	14.44M	1.40M	1.79B
Free Cash Flow	-	-	-	-	-	-	-	-6.39B	26.05B	129.37B	350.29B	-122.56B	17.85B	-30.97B
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	22.76M	0	-
FCF to OCF	-	-	-	-	-	-	-	1512.76%	70.93%	93815.10%	120239.64%	152116.79%	131832.55%	106.14%
Dividend Paid to FCF	-	-	-	-	-	-	-	-	-	-	-	-0.02%	0.00%	-

Earnings

Report Date	May 15, 2015	May 25, 2016	Aug 12, 2016	Nov 11, 2016	Mar 8, 2017	Aug 11, 2017
EPS Estimate	176.30	123.00	0.00	64.00	203.00	-
EPS Actual	-11.00	0.02	0.02	0.01	-46.38	-0.03
Surprise	-106.24%	-99.98%	-	-99.98%	-122.85%	-
Timing	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap76.50B

Enterprise Value-170.66B

Trailing P/E0.00

Forward P/E0.00

Price / Sales3.25

Price / Book0.15

Revenue (TTM)23.54B

Gross Profit (TTM)-31.90B

EBITDA-57.63B

Profit Margin0.00%

Operating Margin-241.41%

Return on Equity-19.37%

Return on Assets-6.86%

Shares Outstanding35.17M

Shares Float16.52M

Beta0.37

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%